<div id="readability-page-1"><p>Shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Get Free Report) rose 7.4% on Tuesday . The company traded as high as $28.17 and last traded at $28.4110. Approximately 588,266 shares traded hands during mid-day trading, a decline of 62% from the average daily volume of 1,533,480 shares. The stock had previously closed at $26.45.</p><div><p><span></span><span>Get <strong>PROCEPT BioRobotics</strong> alerts:</span></p></div><h2>Wall Street Analyst Weigh In</h2><ul><li>3 Underrated Robotics Stocks Poised for Huge Gains</li></ul><p>Several research firms have weighed in on PRCT. Oppenheimer  reissued a &#34;market perform&#34; rating on shares of PROCEPT BioRobotics in a research report on Thursday, February 26th. Robert W. Baird initiated coverage on PROCEPT BioRobotics in a research report on Friday, March 6th. They issued a &#34;neutral&#34; rating and a $30.00 price objective on the stock. Bank of America lowered PROCEPT BioRobotics from a &#34;neutral&#34; rating to an &#34;underperform&#34; rating and decreased their target price for the stock from $38.00 to $20.00 in a research note on Thursday, February 26th. Leerink Partners cut their price objective on PROCEPT BioRobotics from $55.00 to $30.00 and set an &#34;outperform&#34; rating for the company in a report on Thursday, February 26th. Finally, Piper Sandler  restated an &#34;overweight&#34; rating and issued a $35.00 target price (up from $28.00) on shares of PROCEPT BioRobotics in a research note on Thursday, April 30th. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, PROCEPT BioRobotics  has a consensus rating of &#34;Hold&#34; and a consensus price target of $41.45.</p><p><b>Check Out Our Latest Report on PROCEPT BioRobotics</b></p><h2>PROCEPT BioRobotics Stock Up 7.7%</h2><ul><li>Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?</li></ul><p>The company has a market capitalization of $1.62 billion, a PE ratio of -15.66 and a beta of 0.83. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.73 and a quick ratio of 5.51. The company has a 50-day moving average of $25.06 and a two-hundred day moving average of $29.17. </p><p>PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.01). PROCEPT BioRobotics had a negative net margin of 31.82% and a negative return on equity of 27.70%. The business had revenue of $83.13 million during the quarter, compared to analysts' expectations of $80.52 million. During the same quarter in the previous year, the firm earned ($0.45) earnings per share. PROCEPT BioRobotics's revenue was up 20.1% on a year-over-year basis.  Sell-side analysts anticipate that  PROCEPT BioRobotics Corporation will post -1.53 earnings per share for the current fiscal year. </p><h2>Insider Transactions at PROCEPT BioRobotics</h2><ul><li>Why Intuitive Surgical Stock is Dominating the Medical Sector</li></ul><p>In other news, EVP Alaleh Nouri sold 5,363 shares of PROCEPT BioRobotics stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $25.96, for a total value of $139,223.48. Following the sale, the executive vice president directly owned 105,354 shares of the company's stock, valued at approximately $2,734,989.84. The trade was a 4.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Antal Rohit Desai bought 98,699 shares of PROCEPT BioRobotics stock in a transaction dated Monday, March 9th. The stock was purchased at an average cost of $24.55 per share, for a total transaction of $2,423,060.45. Following the completion of the acquisition, the director directly owned 426,262 shares of the company's stock, valued at approximately $10,464,732.10. The trade was a 30.13% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have bought 426,262 shares of company stock valued at $10,483,091 and have sold 23,229 shares valued at $573,466. Insiders own  17.40% of the company's stock. </p><h2>Institutional Investors Weigh In On PROCEPT BioRobotics</h2><p>Several large investors have recently added to or reduced their stakes in the stock. Prosight Management LP grew its stake in shares of  PROCEPT BioRobotics by 1,692.4% during the fourth quarter. Prosight Management LP now owns 1,380,000 shares of the company's stock valued at $43,415,000 after buying an additional 1,303,009 shares during the last quarter.  Alliancebernstein L.P. grew its stake in shares of  PROCEPT BioRobotics by 58.6% during the third quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company's stock valued at $122,052,000 after buying an additional 1,262,928 shares during the last quarter.  T. Rowe Price Investment Management Inc. grew its stake in shares of  PROCEPT BioRobotics by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company's stock valued at $102,919,000 after buying an additional 1,218,815 shares during the last quarter.  ArrowMark Colorado Holdings LLC grew its stake in shares of  PROCEPT BioRobotics by 229.7% during the third quarter. ArrowMark Colorado Holdings LLC now owns 1,128,288 shares of the company's stock valued at $40,269,000 after buying an additional 786,094 shares during the last quarter.  Finally, Mackenzie Financial Corp grew its stake in shares of  PROCEPT BioRobotics by 105.2% during the third quarter. Mackenzie Financial Corp now owns 1,454,434 shares of the company's stock valued at $51,909,000 after buying an additional 745,778 shares during the last quarter. 89.46% of the stock is owned by institutional investors. </p><h2>PROCEPT BioRobotics Company Profile</h2> (Get Free Report)<p>PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company's technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.  </p><p>The company's flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than PROCEPT BioRobotics</li><li>AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?</li><li>Axon Surged After Earnings and Is Still Down Over 50% From Highs</li><li>The Event That Could Redefine Apple’s Summer Rally</li><li>Hims &amp; Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in PROCEPT BioRobotics Right Now?</h2><p>Before you consider PROCEPT BioRobotics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.</p><p>While PROCEPT BioRobotics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PRCT

LABU

SBIO

<p>Shares of PROCEPT BioRobotics (NASDAQ:PRCT) rose 7.4% to $28.41 on Tuesday, with a trading volume of 588,266 shares. Analysts have mixed ratings on the stock, with Oppenheimer maintaining a "market perform" rating, while Bank of America downgraded it to "underperform" with a target price of $20. The company reported a revenue increase of 20.1% year-over-year, but missed EPS estimates. Insider trading activity includes significant purchases and sales. The stock has a consensus rating of "Hold" and a price target of $41.45.</p>

PROCEPT BioRobotics (NASDAQ:PRCT) Trading Up 7.4% - Should You Buy?